NOVN.VX - Novartis AG

Swiss - Swiss Delayed Price. Currency in CHF
75.56
-0.10 (-0.13%)
At close: 5:30PM CEST
Stock chart is not supported by your current browser
Previous Close75.66
Open76.08
Bid75.56 x 373700
Ask76.60 x 1281100
Day's Range75.56 - 76.80
52 Week Range74.22 - 88.30
Volume4,646,855
Avg. Volume4,931,649
Market Cap170.103B
Beta1.11
PE Ratio (TTM)22.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.80 (3.60%)
Ex-Dividend Date2018-03-06
1y Target EstN/A
  • Benzinga2 days ago

    Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...

  • Should You Expect Novartis AG (VTX:NOVN) To Continue Delivering An ROE Of 11.33%?
    Simply Wall St.3 days ago

    Should You Expect Novartis AG (VTX:NOVN) To Continue Delivering An ROE Of 11.33%?

    Novartis AG (SWX:NOVN) delivered an ROE of 11.33% over the past 12 months, which is an impressive feat relative to its industry average of 10.44% during the same period. OnRead More...

  • The Wall Street Journal4 days ago

    [$$] Cohen Probe Trips Up Bridgewater Plan for Board

    Bridgewater Associates was close to bringing on Joseph Jimenez, the former chief executive of Novartis AG, but may back off in the wake of public revelations about his role in payments to President Donald Trump’s personal attorney, people familiar with the matter said. Mr. Jimenez has been thrust into the international spotlight in recent weeks for directing $1.2 million to Mr. Trump’s attorney, Michael Cohen, who is under federal investigation.

  • The Wall Street Journal4 days ago

    New Migraine Drugs Offer Hope to Sufferers

    Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.

  • Does Novartis AG’s (NYSE:NVS) Debt Level Pose A Problem?
    Simply Wall St.4 days ago

    Does Novartis AG’s (NYSE:NVS) Debt Level Pose A Problem?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Novartis AG (NYSE:NVS) a safer option. Big corporations are much sought after by risk-averse investorsRead More...

  • TheStreet.com7 days ago

    CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

    After a heated week of litigation battles, CBS on Thursday proceeded with a board meeting it had scheduled to vote on whether to dilute the voting power of National Amusements Inc., a company controlled by Shari Redstone. This came after a court decision that said CBS could not prevent Redstone from changing CBS's bylaws to prevent that from occurring. All of which means CBS directors and Redstone will be back in court soon to fight over voting control, with Redstone pushing to combine CBS with Viacom, unless of course, both sides instead consider the option to auction the media company.

  • Reuters7 days ago

    After hullabaloo, Greek lawmakers drop Novartis probe against ex ministers

    Greece's parliament has no jurisdiction to investigate the role of ten politicians in alleged bribes by Swiss drugmaker Novartis, lawmakers ruled on Saturday, in a controversy which has further polarized a deeply divided political landscape. Greek prosecutors were probing allegations from three individuals suggesting doctors and public officials had accepted kickbacks in a period spanning 2006 to 2015. Ten public officials who served under socialist and conservative governments over that period say the allegations, which they denied, was a 'sick' mud-slinging campaign fabricated by the leftist-led government.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks7 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • TheStreet.com7 days ago

    Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

    said late Thursday, May 17, they have obtained approval from the U.S. Food and Drug Administration for Aimovig, a migraine prevention drug for adults. The drug is the first treatment green-lighted by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor, thought to play a key role in the disease. "We believe Amgen will benefit significantly from its first mover advantage and ultimately retain 35-40% market share long term," Leerink Partners LLC analyst Geoffrey C. Porges wrote in a note on Friday.

  • Benzinga8 days ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • MarketWatch8 days ago

    FDA approves anti-migraine drug from Novartis, Amgen

    Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.

  • The Wall Street Journal8 days ago

    [$$] Novartis Top Lawyer Departs Over Cohen Payments

    ZURICH——A top executive at Swiss drugmaker Novartis AG is stepping down amid the controversy over payments that corporations made to a company owned by U.S. President Donald Trump’s longtime personal lawyer . Novartis said Wednesday that general counsel Felix Ehrat, 61 years old, is retiring from the company in connection with $1.2 million in payments it made over the course of a year to Michael Cohen’s shell company, Essential Consultants LLC. It was the second high-profile departure in less than a week in relation to payments to the company.

  • Missing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report
    CNBC8 days ago

    Missing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report

    A law enforcement official leaked a suspicious activity report about Trump lawyer Michael Cohen and payments by Novartis and AT&T to his Essential Consultants company, The New Yorker reports.

  • The Wall Street Journal9 days ago

    [$$] The Novartis-Cohen Connection Explained

    Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it has drawn the attention of prosecutors at home. Novartis is a Basel-based multinational pharmaceutical company that makes a number of drugs, including treatments for cancer, heart conditions, and autoimmune diseases.

  • Novartis General Counsel Out Over Cohen Contract
    Bloomberg9 days ago

    Novartis General Counsel Out Over Cohen Contract

    Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's ...

  • MarketWatch9 days ago

    Here’s how Novartis’s former CEO explained hiring Michael Cohen

    Joseph Jimenez, the former chief executive of Novartis, has an explanation for why the Swiss pharmaceutical lavished President Donald Trump’s personal lawyer Michael Cohen with a $1.2 million consulting contract. The hiring of Cohen by Novartis (NVS) , AT&T Inc. (XNYS:T) and Korea Aerospace Industries — revealed by the lawyer of the adult-film star who has alleged having an affair with Trump — has set off a firestorm in Washington and opened up the companies to potential legal liability.

  • How Trump's Fix-It Man Became a $1.2 Million Headache for Novartis
    Bloomberg9 days ago

    How Trump's Fix-It Man Became a $1.2 Million Headache for Novartis

    When Michael Cohen showed up at Novartis AG last year proposing to help the drugmaker navigate the Donald Trump administration, it sounded like a promising opportunity. Cohen had, after all, served as an attorney for Trump and had close ties to the new president. It didn’t take long for Novartis to conclude Cohen was full of hot air.

  • Novartis top lawyer exits over Trump attorney deal 'mistake'
    Reuters9 days ago

    Novartis top lawyer exits over Trump attorney deal 'mistake'

    Novartis's top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behaviour.

  • Novartis top lawyer exits over Trump attorney deal 'mistake'
    Reuters9 days ago

    Novartis top lawyer exits over Trump attorney deal 'mistake'

    Novartis's (NOVN.S) top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behavior.

  • Novartis Lawyer to Step Down After Cohen Payments
    Bloomberg9 days ago

    Novartis Lawyer to Step Down After Cohen Payments

    Top Novartis lawyer to step down over Michael Cohen payments https://bloom.bg/2L3GjUI #tictocnews (Source: Bloomberg)

  • Forbes9 days ago

    Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million

    Joseph Jimenez, who served as chief executive of the Basel, Switzerland-based drug giant Novartis for eight years, says that he takes full responsibility for the company's decision to hire Michael Cohen, President Donald Trump's former lawyer, through a $1.2 million consulting agreement. “I brought him into the company, so I would … we as a company were looking for people who could help us on policy,” Jimenez says when asked if the decision to hire Cohen was his.

  • Novartis general counsel resigns over deal with Trump lawyer
    Associated Press9 days ago

    Novartis general counsel resigns over deal with Trump lawyer

    Swiss pharmaceutical giant Novartis said Wednesday that its top lawyer is stepping down over a deal to hire U.S. President Donald Trump's personal lawyer, Michael Cohen, as a consultant. Company spokesman Eric Althoff said last week that Novartis had entered into a one-year agreement with Essential Consultants in February 2017 — a month after Trump's inauguration — to focus on health care policy.

  • The Wall Street Journal9 days ago

    Novartis Is on a Journey

    To rebuild trust with society, of course.

  • Novartis General Counsel Out Over Cohen Contract
    Bloomberg Video9 days ago

    Novartis General Counsel Out Over Cohen Contract

    May.16 -- Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's Drew Armstrong reports on "Bloomberg Markets: Balance of Power."

  • Top Novartis Lawyer quits over Cohen payments
    Yahoo Finance Video9 days ago

    Top Novartis Lawyer quits over Cohen payments

    The Swiss drugmaker's top lawyer quit following the company's payments to President Trump's personal attorney Michael Cohen. Yahoo Finance's Seana Smith, Melody Hahm and Myles Udland discuss.